Interobserver variability in assessing treatment response of hepatocellular carcinoma to transarterial chemoembolization: A comparative study of LIRADS TR and mRECIST criteria in South America

Abstract

Hepatocarcinoma (HCC) is a major cause of worldwide morbidity and mortality. Transarterial chemoebolization (TACE) is a frequent management strategy in cases of unresectability. The imaging response assessment to treatment is complex and there are different strategies that are not universal and whose performance has not been compared.